Guidance on nitrosamine impurities in medications. : H164-327/2024E-1-PDF

"This guidance represents Health Canada's current thinking and recommendations on issues related to N-nitrosamine impurities (nitrosamine impurities or nitrosamines). This guidance may be subject to change as new information becomes available and if further guidance is needed for applicants and market authorization holders (MAHs). A questions-and-answers (Q&A) document on nitrosamines was issued to MAHs on November 26, 2019. This document has undergone a number of revisions and has been further updated as a guidance document and to provide additional details to active pharmaceutical ingredient (API) manufacturers, drug product manufacturers, MAHs and importers of APIs and drug products. In this guidance document, changes from the previous version are identified with the descriptors "new" or "updated" (as applicable). Information on a similar theme is grouped together under general headings (for example, General, Safety and Quality). …"--Background, page 1.

Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.938524&sl=1

Renseignements sur la publication
Ministère/Organisme Canada. Health Canada, issuing body.
Titre Guidance on nitrosamine impurities in medications.
Type de publication Monographie
Langue [Anglais]
Autres langues publiées [Français]
Édition précédente Guidance on nitrosamine impurities in medications. (March 2024)
Format Électronique
Document électronique
Note(s) Issued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments.
"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products."
"Date adopted: 2024-05-31."
"Effective date: 2024-05-31."
"Pub.: 240217"--Verso of cover.
Includes bibliographical references.
Information sur la publication Ottawa, ON : Health Canada = Santé Canada, May 2024.
©2024
Description 1 online resource (iii, 56 pages) : illustrations (some colour)
ISBN 9780660720524
Numéro de catalogue
  • H164-327/2024E-1-PDF
Numéro de catalogue du ministère 240217
Descripteurs Nitrosoamines -- Risk assessment -- Canada.
Drugs -- Risk assessment -- Canada.
Biologicals -- Risk assessment -- Canada.
Radiopharmaceuticals -- Risk assessment -- Canada.
Pharmaceutical policy -- Canada.
Demander des formats alternatifs
Pour demander une publication dans un format alternatif, remplissez le formulaire électronique des publications du gouvernement du Canada. Utilisez le champ du formulaire «question ou commentaire» pour spécifier la publication demandée.
Date de modification :